Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Alx Oncology Holdings (ALXO) Income from Continuing Operations (2019 - 2026)

Alx Oncology Holdings' Income from Continuing Operations history spans 5 years, with the latest figure at 91066000.0 for Q4 2023.

  • On a quarterly basis, Income from Continuing Operations rose 28.49% to 91066000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was 24685000.0, a 12.83% decrease, with the full-year FY2025 number at 497000.0, up 99.63% from a year prior.
  • Income from Continuing Operations hit 91066000.0 in Q4 2023 for Alx Oncology Holdings, up from 50989000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ALXO hit a ceiling of 91066000.0 in Q4 2023 and a floor of 50989000.0 in Q3 2023.
  • Historically, Income from Continuing Operations has averaged 6536052.63 across 5 years, with a median of 11331000.0 in 2020.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 234.46% in 2020 and later soared 3265.38% in 2022.
  • Tracing ALXO's Income from Continuing Operations over 5 years: stood at 7764000.0 in 2019, then soared by 322.41% to 17268000.0 in 2020, then tumbled by 87.8% to 2106000.0 in 2021, then soared by 3265.38% to 70875000.0 in 2022, then grew by 28.49% to 91066000.0 in 2023.
  • Business Quant data shows Income from Continuing Operations for ALXO at 91066000.0 in Q4 2023, 50989000.0 in Q3 2023, and 34483000.0 in Q2 2023.